Full-Time

Director Associate

Data Standards

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$141.5k - $268.5k/yr

+ Long-Term Incentive Programs

Waukegan, IL, USA

Hybrid

Hybrid role: on-site Tue-Thu, remote Mon & Fri.

Bachelor's

Category
Biology & Biotech (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelors of Science
  • 12+ years of relevant clinical research experience (or 10+ years with a Masters)
  • Expert level of knowledge of at least 3 areas of clinical data standards, and high level of knowledge in at least one additional area. (Areas include CDASH, SDTM, ADaM, define.xml, controlled terminology and metadata management.)
  • Familiarity with other clinical data standards including BRIDG, ODM and SHARE
  • Experience in mapping and converting legacy data into SDTM domains for eCTD submissions. Minimum of two successful submissions of CDISC compliant data.
  • Knowledge of international regulations, requirements and guidance associated with clinical data standards and the preparation of data sets for regulatory submission.
  • Experience with metadata repository technology and its application in clinical data standards processes and experience with data standards governance
  • Experience in management of metadata to support efficient use of systems and processes
Responsibilities
  • Responsible for compliance with applicable Corporate and Divisional Polices and procedures
  • Industry Standards - Maintains complete and in-depth understanding of all CDISC guidance documents and implementation guides as well as FDA guidance and regulation regarding electronic submission of data. Keeps abreast of industry trends in data mapping, data management, standards compliance methodologies, metadata management and data warehousing.
  • eCRF Design - Demonstrates extensive understanding of CDASH and SDTM standards and concepts. Able to critically review eCRF designs to ensure compatibility/conformance with CDASH/SDTM standards. Recognizes limitations if eCRF design and correct flaws proactively.
  • SDTM Conformance Mapping - Demonstrate extensive understanding of SDTM, Standard Terminology and common coding dictionaries. Reviews SDTM conformance mapping specifications and corrects flaws proactively. Provide input and CDISC expertise to cross-functional activities such as mapping of source data to SDTM.
  • CDISC Validation Tools - Demonstrates knowledge of rules for SDTM and the associated define.xml file or rules for ADaM and the associated define.xml file and able to appropriately interpret results from common validation tools. Executes validation tools and collaborates with other functions to resolve identified issues. Ensure any unresolved issues are appropriately documented (for example in the FDA's Data Reviewer's Guides)
  • Metadata Repository - Responsible for managing libraries of CDISC-related metadata, terminology and related standards within the metadata repository. Provides governance oversight to Manager, Data Standards to ensure consistency in metadata.
  • Policies & Procedures - Assist in the development of data standards policies, procedures and practices.
  • Communication - Clearly communicates an understanding of clinical data standards concepts, clinical principles, and regulatory guidance and acts in accordance with those principles. Effectively presents data standards concepts and logical arguments to statistical programmers, statisticians, data scientists, clinical development and regulatory. Able to diplomatically and persuasively represent the interests of the Data Standards group in cross-functional initiatives.
  • Training & Mentoring - Be compliant with training requirements. Effectively mentor peers, Manager, Data Standards, Sr Data Standards Analysts and Data Standards Analysts with regard to data standards and functional operations. Train new Data Standards Analysts on process and systems related to the management and implementation of data standards.
  • CDISC involvement - Maintains external reputation of a clinical data standards expert. Ensures consolidated review comments from Data Standards group and Statistical Programming are provided for applicable CDISC standards released for public review. Submits at least one abstract per year for presentation at a CDISC Interchange.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.